一分钟看懂
这是一项关于非小细胞肺癌的III 期研究，登记的药物或干预包括Savolitinib；Placebo，当前状态为研究进行中，已停止招募。登记地点显示中国广州有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Savolitinib；Placebo · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Guangdong General Hospital · 广州
公开的入选条件
- 1. Fully aware of this study and voluntary to sign the informed consent form, and being willing and able to comply with the study procedure;
- 2. Age ≥ 18
- 3. In accordance with the Eighth Edition of TNM Staging of Lung Cancer by the International Association for the Study of Lung Cancer and American Joint Committee on Cancer, and patients with histologically or cytologically confirmed unresectable locally advanc
- 4. Carrying two common EGFR mutations clearly related with the sensitivity to EGFR-TKI (i.e., exon 19 deletion, and L858R) and c-MET overexpression
- 5. Having measurable lesions (in accordance with RECIST 1.1 criteria);
- 6. ECOG Performance Status score 0 or 1, or Karnofsky score ≥80;
- 7. Survival is expected to exceed 12 weeks;
- 8. No any previous systematic antitumor therapy for advanced/metastatic disease;
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05009836；登记信息更新于 2026-09-15。